Consumers across the EU are set to benefit from a new OTC option to relieve allergy symptoms after the European Medicines Agency gave the green light to the centralised switch of Ratiopharm GmbH’s Desloratadine Ratiopharm.
EMA Recommends EU-Wide Desloratadine Switch
Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.
